Dr Fiona Marshall joins MSD from Sosei from Heptares, the UK biotech company she co-founded more than a decade ago, and which was acquired by Sosei in 2015.
NHS authorities could begin to use the reimbursement system as a “stick” to ensure doctors prescribe cheaper biosimilar medicines amid varied uptake in different regions.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.